AbbVie | ABBV - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
AbbVie USD 9.39B 4.16B 2026-03
Abbott USD 6.8B 1.72B 2026-03
ALKERMES USD 351.55M 37.02M 2026-03
Amgen USD 12.04B 2.91B 2026-03
AstraZeneca USD 7.56B 1.85B 2026-03
Biogen USD 3.38B 374.2M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Coherus Biosciences USD 88.88M 14.47M 2025-12
Eisai JPY 301.65B 16.27B 2025-09
Eli Lilly USD 5.28B 1.99B 2026-03
Gilead Sciences USD 7.56B 234M 2025-12
GlaxoSmithKline GBP 3.44B 292M 2026-03
Infinity Pharmaceuticals USD 17.75M 7.99M 2023-06
J&J USD 21.69B 1.98B 2026-03
Medtronic USD 1.15B 135M 2025-12
Merck USD 5.33B 9.24B 2026-03
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Novartis USD 6.88B 4.56B 2026-03
Pacira USD 144.31M 14.24M 2026-03
Perrigo USD 531.6M 99.5M 2025-12
Pfizer USD 1.7B 561M 2026-03
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Roche Holding CHF 7.55B 579M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
UCB EUR 1.57B 1.14B 2024-12
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
United Therapeutics USD 1.28B 277.4M 2026-03
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03
Zoetis USD 1.94B 369M 2026-03